Uncategorized

Micron Biomedical Announces The Lancet Publication of Positive Phase 1/2 Data From First Clinical Trial of Needle-Free Vaccines in Children

Micron Biomedical, a life science company developing first-in-class dissolvable microarray-based products that simplify and improve the transport, storage, and administration of drugs and vaccines, today announced the publication of its positive Measles and Rubella (MR) Phase 1/2 trial data in The Lancet Medical Journal.

Micron Biomedical Announces The Lancet Publication of Positive Phase 1/2 Data From First Clinical Trial of Needle-Free Vaccines in Children Read More »

Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings

Ardelyx, Inc. today announced that additional data supporting XPHOZAH ® (tenapanor) will be presented at the National Kidney Foundation (NKF) 2024 Spring Clinical Meetings, to be held May 14-18, 2024, in Long Beach, California.

Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings Read More »

Scroll to Top